Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Purpose of review: To help clinicians to distinguish between myositis (and other immune-mediated and immunosuppressant-responsive disorders) and its many clinical mimics. Recent findings: Increasing experience has shown that findings from conventional investigations, such as muscle biopsy, can be misleading. More specialist investigations, notably autoantibody screening, immunocytochemical techniques, and evolving DNA technologies, are powerful tools but experience is currently largely limited to specialist centres-and even these techniques are open to misinterpretation. Summary: Misdiagnosis is hazardous to the patient. Treatable conditions may be missed, or patients subjected inappropriately to potentially toxic drug treatments. Judicious use of clinical skills alone should help reduce these risks.

Original publication




Journal article


Current Opinion in Rheumatology

Publication Date





663 - 670